Full TitleStudy of the Efficacy, Safety and Quality of Life after TOOKAD Soluble Vascular Targeted Photodynamic therapy (VPT) for Minimally Invasive Treatment of Localized Intermediate Risk Prostate Cancer
This study is assessing a new treatment called TOOKAD-Soluble vascular-targeted photodynamic therapy in men with previously untreated localized intermediate-risk prostate cancer. Patients receive a dose of the drug TOOKAD-Soluble intravenously (by vein). When laser light is applied fiberoptically into the part of the prostate where the cancer is, the drug in that tissue becomes activated to kill cancer cells. This treatment is very targeted because only the drug in the area exposed to the laser light becomes activated, sparing other tissues from the effects of the drug.
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have localized intermediate-risk prostate cancer (Gleason score 7, 3+4) that is confined to only half of the gland and has not yet been treated.
- This study is for men age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Jonathan Coleman at 646-422-4432.